Department of Advanced Biomedical Sciences, Federico II University of Naples, Via S Pansini 5, 80131 Napoli, Italy.
Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Int J Mol Sci. 2024 Jul 25;25(15):8128. doi: 10.3390/ijms25158128.
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by unexplained left ventricular hypertrophy (LVH), diastolic dysfunction, and increased sudden-death risk. Early detection of the phenotypic expression of the disease in genetic carriers without LVH (Gen+/Phen-) is crucial for emerging therapies. This clinical study aims to identify echocardiographic predictors of phenotypic development in Gen+/Phen-. Sixteen Gen+/Phen- (one subject with troponin T, six with myosin heavy chain-7, and nine with myosin-binding protein C3 mutations), represented the study population. At first and last visit we performed comprehensive 2D speckle-tracking strain echocardiography. During a follow-up of 8 ± 5 years, five carriers developed LVH (LVH+). At baseline, these patients were older than those who did not develop LVH (LVH-) (30 ± 8 vs. 15 ± 8 years, = 0.005). LVH+ had reduced peak global strain rate during the isovolumic relaxation period (SRIVR) (0.28 ± 0.05 vs. 0.40 ± 0.11 1/s, = 0.048) and lower global longitudinal strain (GLS) (-19.8 ± 0.4 vs. -22.3 ± 1.1%; < 0.0001) than LVH- at baseline. SRIVR and GLS were not correlated with age (overall, > 0.08). This is the first HCM study investigating subjects before they manifest clinically significant or relevant disease burden or symptomatology, comparing at baseline HCM Gen+/Phen- subjects who will develop LVH with those who will not. Furthermore, we identified highly sensitive, easily obtainable, age- and load-independent echocardiographic predictors of phenotype development in HCM gene carriers who may undergo early preventive treatment.
肥厚型心肌病(HCM)是一种遗传性疾病,其特征为左心室肥厚(LVH)、舒张功能障碍和猝死风险增加。在没有 LVH(Gen+/Phen-)的遗传携带者中早期发现疾病表型表达对于新兴疗法至关重要。本临床研究旨在确定 Gen+/Phen-中表型发展的超声心动图预测因子。16 名 Gen+/Phen-(一名肌钙蛋白 T 阳性,六名肌球蛋白重链-7 阳性,九名肌球蛋白结合蛋白 C3 突变阳性)代表研究人群。在首次和末次就诊时,我们进行了全面的二维斑点追踪应变超声心动图检查。在 8±5 年的随访期间,五名携带者出现 LVH(LVH+)。在基线时,这些患者比未发生 LVH(LVH-)的患者年龄更大(30±8 岁比 15±8 岁, =0.005)。LVH+在等容舒张期的峰值整体应变率(SRIVR)(0.28±0.05 比 0.40±0.11 1/s, =0.048)和整体纵向应变(GLS)(-19.8±0.4 比-22.3±1.1%;<0.0001)均低于 LVH-。SRIVR 和 GLS 与年龄无相关性(总体,>0.08)。这是第一项在出现临床显著或相关疾病负担或症状之前研究 HCM 的研究,比较了基线时将发生 LVH 的 HCM Gen+/Phen-受试者与不会发生 LVH 的受试者。此外,我们确定了在可能接受早期预防性治疗的 HCM 基因携带者中,具有高度敏感性、易于获得、与年龄和负荷无关的表型发展的超声心动图预测因子。